文献速递慢性肾脏病肾血管病与高血压

CKD进展对英国当代糖尿病队列心血管疾病风险的影响

Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes.
PubMed 文献 · Kidney Int Rep · 2020-08-07

研究基于英国CPRD数据库中30,222例新诊断CKD的糖尿病患者,评估eGFR斜率与CVD风险的关联。结果显示,更新的eGFR斜率下降>-3 ml/min/1.73 m²增加MACE plus(HR=1.45)、心衰(HR=1.50)和心梗(HR=1.39)风险。结论支持CKD是CVD独立危险因素,进展速率与累积状态反映不同风险层面。

要点

  • eGFR斜率下降>-3 ml/min/1.73 m²与MACE plus风险增加独立相关。
  • CKD进展速率和累积eGFR状态分别描述糖尿病患者的心肾风险。
  • 该证据有助于更及时优化糖尿病合并CKD患者的治疗。

核心结论

  • 研究强烈支持CKD是心血管疾病的独立危险因素。
  • 进展速率与累积状态从不同方面描述糖尿病患者的心肾风险。

研究设计与样本

  • 基于英国CPRD GOLD数据库的队列研究,纳入30,222例新诊断CKD的糖尿病患者。
  • 比较多个重叠2年期间计算的更新eGFR斜率与更新平均eGFR对CVD风险的预测价值。

主要发现

  • 更新eGFR斜率和更新平均eGFR均与MACE plus和心衰相关。
  • eGFR斜率下降>-3 ml/min/1.73 m²增加MACE plus风险(校正HR=1.45;95%CI 1.26-1.67)。
  • eGFR斜率下降>-3 ml/min/1.73 m²增加心衰风险(HR=1.50;95%CI 1.27-1.76)。
  • eGFR斜率下降>-3 ml/min/1.73 m²增加心梗风险(HR=1.39;95%CI 1.01-1.91)。

关键数值与推荐

  • eGFR斜率下降>-3 ml/min/1.73 m²为风险分层阈值。
  • MACE plus复合终点包括心衰、心梗和缺血性卒中。

临床怎么用

  • 临床应同时关注糖尿病患者CKD进展速率和累积eGFR状态以评估心血管风险。
  • 对eGFR快速下降者需更及时优化心肾保护治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: It remains unclear whether an increased progression rate of chronic kidney disease (CKD) adds predictive information regarding cardiovascular disease (CVD) risk. The aim of this study was to evaluate the association between CKD progression, based on estimated glomerular filtration rate (eGFR) slope estimates and the risk for CVD. METHODS: We compared the updated eGFR slope calculated over multiple overlapping 2-year periods and the updated mean eGFR. Incident CKD subjects were selected from a prevalent population with diabetes (T2DM). Subjects from the UK Clinical Practice Research Data Link GOLD (CPRD) were followed from CKD diagnosis (n = 30,222) until heart failure (HF), myocardial infarction (MI), ischemic stroke (IS), or a composite end point including all 3 event types (MACE plus), mortality, database dropout, or end of study follow-up. RESULTS: Both the updated eGFR slope and updated mean eGFR were associated with MACE plus and HF. Updated eGFR slope decline of > -3 ml/min/1.73 m2 increased the risk for MACE plus (adjusted hazard ratio [HR] = 1.45; 95% confidence interval [CI], 1.26-1.67), HF (HR = 1.50; 95% CI, 1.27-1.76), and MI (HR = 1.39; 95% CI, 1.01-1.91). CONCLUSIONS: This study strongly supports current evidence that CKD is an independent risk factor for CVD. From a clinical perspective, both rate of progression and cumulative status of CKD describe distinct aspects of the cardiorenal risk among persons with diabetes. This evidence is essential to enable more timely and improved use of treatments in this population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cabrera CS, Lee AS, Olsson M, et al. Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes. Kidney Int Rep. 2020. PMID: 33102957. doi:10.1016/j.ekir.2020.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。